Howard L. McLeod
Impact in
- Pharmacology top 0.01%
- Pharmacogenetics and Drug Metabolism
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
Papers in
- Oncology 201
- Colorectal Cancer Treatments and Studies 82
- Cancer Treatment and Pharmacology 55
- Drug Transport and Resistance Mechanisms 46
-
- Cancer therapeutics and mechanisms 55
- Co-authors
- Sharon Marsh (66 shared papers)William E. Evans (8 shared papers)Teri E. Klein (16 shared papers)Russ B. Altman (10 shared papers)Caroline F. Thorn (5 shared papers)Graeme I. Murray (20 shared papers)Richard M. Goldberg (10 shared papers)Janelle M. Hoskins (18 shared papers)
- Journals
- Pharmacogenomics (49 papers)Journal of Clinical Oncology (27 papers)Pharmacogenetics and Genomics (21 papers)Clinical Cancer Research (17 papers)Clinical Pharmacology & Therapeutics (17 papers)
- Partner nations
- United StatesUnited KingdomChina
In The Last Decade
Howard L. McLeod
476 papers receiving 26.0k citations
Howard L. McLeod's Hit Papers
Peers
Comparison fields: 5 of 192
- Pharmacology 6.6k
- Oncology 10.1k
- Cancer Research 2.9k
- Molecular Biology 9.6k
- Pediatrics, Perinatology and Child Health 2.6k
Countries citing papers authored by Howard L. McLeod
This map shows the geographic impact of Howard L. McLeod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard L. McLeod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard L. McLeod more than expected).
Fields of papers citing papers by Howard L. McLeod
This network shows the impact of papers produced by Howard L. McLeod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard L. McLeod. The network helps show where Howard L. McLeod may publish in the future.
Co-authors
The 25 scholars most cited alongside Howard L. McLeod, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 481 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Doxorubicin pathways Hit paper breakdown → | 2010 | 1292 |
| 2 | Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects Hit paper breakdown → | 2003 | 1262 |
| 3 | Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose Hit paper breakdown → | 2005 | 988 |
| 4 | 2009 | 476 | |
| 5 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update Hit paper breakdown → | 2017 | 406 |
| 6 | 2005 | 391 | |
| 7 | 2005 | 391 | |
| 8 | Genomics and Drug Response Hit paper breakdown → | 2011 | 390 |
| 9 | 2004 | 356 | |
| 10 | 2007 | 349 | |
| 11 | 2002 | 328 | |
| 12 | The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update Hit paper breakdown → | 2014 | 301 |
| 13 | 1996 | 274 | |
| 14 | 2008 | 265 | |
| 15 | 2003 | 249 | |
| 16 | Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. | 2002 | 248 |
| 17 | 2012 | 242 | |
| 18 | 2009 | 239 | |
| 19 | Pharmacogenomics Hit paper breakdown → | 2019 | 238 |
| 20 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy Hit paper breakdown → | 2018 | 237 |
About Howard L. McLeod
Howard L. McLeod is a scholar working on Oncology, Molecular Biology, Pharmacology, Genetics and Cancer Research, having authored 481 papers that have together received 26.6k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (137 papers), Colorectal Cancer Treatments and Studies (82 papers), Cancer Treatment and Pharmacology (55 papers), Cancer therapeutics and mechanisms (55 papers), Cancer Genomics and Diagnostics (50 papers), Drug Transport and Resistance Mechanisms (46 papers), Genetic factors in colorectal cancer (37 papers) and Lung Cancer Treatments and Mutations (25 papers). The work is most often cited by research in Pharmacology (6.6k citations), Oncology (10.1k citations), Cancer Research (2.9k citations), Molecular Biology (9.6k citations) and Pediatrics, Perinatology and Child Health (2.6k citations). Howard L. McLeod has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Sharon Marsh, William E. Evans, Teri E. Klein, Russ B. Altman, Caroline F. Thorn, Graeme I. Murray, Richard M. Goldberg, Janelle M. Hoskins, Daniel Morgensztern and Connie Oshiro. Their work appears in journals such as Pharmacogenomics, Journal of Clinical Oncology, Pharmacogenetics and Genomics, Clinical Cancer Research and Clinical Pharmacology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.